Science Current Events | Science News | Brightsurf.com
 

Adding bavituximab to second-line chemotherapy doubles response rate in late-stage lung cancer patients

September 07, 2012
Patients also had increase in progression free, overall survival rates

Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.

Docetaxel is the standard second-line treatment for stage IIIB and stage IV NS-NSCLC patients. Researchers in this phase II, nine center, double-blind, randomized study evaluated the efficacy and safety of docetaxel plus a placebo (control arm) versus docetaxel plus either 1 mg or 3 mg bavituximab. The 117 evaluable patients were randomized to receive one of the three regimens every 21 days for up to six cycles. Patients received the same regimen for each cycle.

The overall response rate for the 1 mg bavituximab arm was 15 percent and 17.9 percent in the 3 mg arm, approximately double the control arm rate of 7.9 percent. Median progression-free survival was 4.2 and 4.5 months for the bavituximab arms, respectively, compared to three months for the control arm.

The trial was unblinded after 18 months, at which point the median overall survival had been reached in the control arm at 5.4 months (61 percent of patients died); however, neither bavituximab arms had reached median overall survival (fewer than 35 percent of patients died).

"This rigorous phase II trial demonstrates that not only is bavituximab well tolerated when given with docetaxel but it improves response rates, progression free survival and overall survival of second-line chemotherapy in patients with advanced NSCLC," said David Gerber, MD, lead author of the study and an assistant professor of internal medicine at University of Texas Southwestern Medical Center in Dallas who specializes in lung cancer treatment. "If a phase III trial confirms these findings, bavituximab could become a major component of standard treatment for patients with this challenging disease."

The abstract, "Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-small Cell Lung Cancer (Top-line Results)," will be presented during the Plenary Session at 12:30 p.m., Central time on September 7, 2012.

American Society for Radiation Oncology (ASTRO)


Related Bavituximab Current Events and Bavituximab News Articles


ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine (PS)-targeting antibody bavituximab for the treatment of solid tumors.

Peregrine reports new study from Duke shows anti-HIV potential of targeting PS on cells
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells.

Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS) targeting antibodies.

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.

UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.

Arsenic aids tumor imaging when joined to cancer-homing drug, UT Southwestern researchers find
Arsenic linked to a drug that binds to the blood vessels of cancerous tumors provides a powerful imaging agent that could one day allow physicians to detect hard-to-find tumors and more closely monitor cancer's response to therapy, researchers at UT Southwestern Medical Center have found.
More Bavituximab Current Events and Bavituximab News Articles

© 2014 BrightSurf.com